评估乳腺癌放疗风险:来自肺和心脏现代放疗剂量及既往随机试验的证据
该研究结合2010至2015年发表的647种方案的肺和心脏平均剂量(全肺5.7 Gy、全心脏4.4 Gy),以及75项随机试验中40,781名女性的个体患者数据Meta分析,估算现代乳腺癌放疗的长期绝对风险。结果显示,长期持续吸烟者肺癌绝对风险约4%、心脏死亡风险约1%,而非吸烟者分别为0.3%和0.3%;作者认为对长期吸烟者放疗绝对风险可能超过获益,而对大多数非吸烟者(及戒烟者)获益远大于风险,戒烟可大幅降低放疗风险。
要点
- 2010至2015年发表的647种方案平均全肺剂量5.7 Gy、全心脏剂量4.4 Gy,中位照射年份2010年(IQR 2008-2011)。
- Meta分析显示放疗后≥10年肺癌发生RR 2.10(95%CI 1.48-2.98;P<.001),全肺剂量每Gy的ERR 0.11(95%CI 0.05-0.20)。
- 心脏死亡RR 1.30(95%CI 1.15-1.46;P<.001),全心脏剂量每Gy的ERR 0.04(95%CI 0.02-0.06)。
核心结论
- 对长期吸烟者,现代放疗的绝对风险可能超过获益;对大多数非吸烟者(及戒烟者),放疗获益远大于风险。
- 吸烟可决定放疗对死亡率的净效应,但戒烟可大幅降低放疗风险。
研究设计与样本
- 第一,对2010至2015年发表的乳腺癌放疗方案中肺和心脏剂量进行系统文献综述。
- 第二,对75项随机试验中40,781名随机分配至乳腺癌放疗或不放疗的女性进行个体患者数据Meta分析,得出第二原发癌和死因别死亡率的率比(RR)及每Gy肺癌发生和心脏死亡的超额RR(ERR)。
- 第三,将试验中每Gy肺或心脏ERR与2010至2015年剂量结合,应用于基于人群数据中的当前吸烟者和非吸烟者肺癌及心脏死亡率;吸烟状态不可获得。
主要发现
- 2010至2015年发表的647种方案平均剂量为全肺5.7 Gy、全心脏4.4 Gy;中位照射年份为2010年(四分位距[IQR] 2008至2011)。
- Meta分析基于134例肺癌得出放疗后≥10年肺癌发生RR 2.10(95%CI 1.48至2.98;P<.001),相当于全肺剂量每Gy的ERR 0.11(95%CI 0.05至0.20)。
- 心脏死亡RR 1.30(95%CI 1.15至1.46;P<.001),基于1,253例心脏死亡;详细分析表明全心脏剂量每Gy的ERR 0.04(95%CI 0.02至0.06)。
- 现代放疗估算的绝对风险为:肺癌,长期持续吸烟者约4%、非吸烟者0.3%;心脏死亡,吸烟者约1%、非吸烟者0.3%。
临床怎么用
- 作者认为,对长期吸烟者,现代放疗的绝对风险可能超过获益;对大多数非吸烟者(及戒烟者),放疗获益远大于风险。
- 作者指出,吸烟可决定放疗对死亡率的净效应,但戒烟可大幅降低放疗风险。
局限性
- 吸烟状态不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Radiotherapy reduces the absolute risk of breast cancer mortality by a few percentage points in suitable women but can cause a second cancer or heart disease decades later. We estimated the absolute long-term risks of modern breast cancer radiotherapy. Methods First, a systematic literature review was performed of lung and heart doses in breast cancer regimens published during 2010 to 2015. Second, individual patient data meta-analyses of 40,781 women randomly assigned to breast cancer radiotherapy versus no radiotherapy in 75 trials yielded rate ratios (RRs) for second primary cancers and cause-specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality. Smoking status was unavailable. Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combined and applied to current smoker and nonsmoker lung cancer and cardiac mortality rates in population-based data. Results Average doses from 647 regimens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart. The median year of irradiation was 2010 (interquartile range [IQR], 2008 to 2011). Meta-analyses yielded lung cancer incidence ≥ 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46; P < .001) on the basis of 1,253 cardiac deaths. Detailed analyses indicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose. Estimated absolute risks from modern radiotherapy were as follows: lung cancer, approximately 4% for long-term continuing smokers and 0.3% for nonsmokers; and cardiac mortality, approximately 1% for smokers and 0.3% for nonsmokers. Conclusion For long-term smokers, the absolute risks of modern radiotherapy may outweigh the benefits, yet for most nonsmokers (and ex-smokers), the benefits of radiotherapy far outweigh the risks. Hence, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substantially reduces radiotherapy risk.
引用
- Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017. PMID: 28319436. doi:10.1200/JCO.2016.72.0722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。